You are here: Industry Insights > SMA

News List

Biogen’s SMA drug Spinraza to be available on NHS pharmaceutical-technology
May 22, 2019
The UK’s National Health Service (NHS) has signed a managed access agreement to fund Biogen’s antisense oligonucleotide (ASO) Spinraza (nusinersen) for a limited time to ascertain its effectiveness as a treatment for 5q spinal muscular atrophy (SMA).
NHS England agree to pay for Biogen's $750,000 a year SMA treatment Spinraza pharmafile
May 16, 2019
NHS England has agreed to pay an undisclosed price for Biogen’s spinal muscle atrophy (SMA) treatment Spinraza.
Novartis reveals promising interim Phase 3 data for gene therapy Zolgensma in spinal muscular atrophy pharmafile
April 23, 2019
Novartis has revealed new interim data from its Phase 3 trial investigating the efficacy of its gene therapy Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101) in the treatment...
New data reinforce effectiveness of Novartis’ Zolgensma for SMA pharmatimes
April 21, 2019
New AveXis data has reinforced the effectiveness of Novartis’ spinal muscular atrophy (SMA) Type I drug, Zolgensma (onasemnogene abeparvovec-xioi).
AveXis Data Reinforce Effectiveness of Zolgensma in Treating Spinal Muscular Atrophy (SMA) Type 1 drugs
April 18, 2019
AveXis Data Reinforce Effectiveness of Zolgensma in Treating Spinal Muscular Atrophy (SMA) Type 1.
New data reinforce effectiveness of Novartis’ Zolgensma for SMA pharmatimes
April 18, 2019
The Phase III STR1VE data show prolonged event-free survival, early and rapid increases in The Children's Hospital of ……
Late-stage pipeline drugs could compete with only treatment for SMA europeanpharmaceuticalreview
April 10, 2019
A number of drugs currently in their late stages in the development process could see competition for nusinersen, the only current SMA treatment, rise…
China National Medical Products Association Approves SPINRAZA americanpharmaceuticalreview
March 01, 2019
Biogen announced that SPINRAZA has been approved by the China National Medical Products Association for the treatment of 5q spinal muscular atrophy,expanding the company’s presence in China.
Roche gets PRIME designation for SMA drug in Europe pharmaceutical-technology
December 20, 2018
Roche has secured PRIME designation from the European Medicines Agency (EMA) for its risdiplam (RG7916) medicine to treat spinal muscular atrophy (SMA).
Novartis says $4m price is reasonable for SMA gene therapy pharmaphorum
December 14, 2018
Novartis says it thinks its one-off gene therapy for spinal muscular atrophy (SMA) could deliver value for money even if its price was set upwards of $4 million – which would set a record for a pharmaceutical product.

Previous page 1 2 3 4 5 6 Next page